Is OCGN Worth Buying in 2026?

Ocugen, Inc. Common Stock

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-04-19

Here’s whether Ocugen, Inc. Common Stock (OCGN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.53% over 10 days); RSI 58 — healthy momentum range; strong 1-year return of +204.7%; 3-month momentum positive (+17.8%). Concerns: declining volume on rally — weak conviction (0.52x 30d avg). Currently 27.0% off its 52-week high. Score: +6/7.

Ready to act on this? 📈 Trade on Webull

OCGN is in a confirmed uptrend, trading above both its 50-day ($1.82) and 200-day ($1.44) moving averages. An RSI of 57.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +204.7% compares to +35.1% for SPY (beat the market by 169.6%). The current 27.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $30,465 today
vs. S&P 500 (SPY) — same period beat market by 169.6%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($1.44)
Above 50-day MA ($1.82)
RSI(14) neutral zone (30–70) — currently 57.9
Positive return (+204.7%)
!Within 10% of period high (−27.0%)
Period Range $1.99
$0.64 $2.73
RSI (14) 57.9
0 · OversoldOverbought · 100

Key Metrics

Price$1.99
Period Return+204.7%
Period High$2.73
Period Low$0.64
Drawdown−27.0%
MA-50$1.82
MA-200$1.44
RSI (14)57.9
Avg Volume (30d)10.0M
vs. SPYbeat by 169.6%
Return Rank#101 of 996

Trade OCGN

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers